Self-nanoemulsifying drug delivery system for nebulization: fabrication and evaluation for systemic delivery of atorvastatin
Muhammad Danish Saeed,Kifayat Ullah Shah,Muhammad Fahad,Shefaat Ullah Shah,Syed Faisal Badshah,Hassan Shah,Irfan Anjum,Gamal A. Shazly,Mohammed Bourhia
DOI: https://doi.org/10.1007/s00210-024-03494-w
2024-10-04
Naunyn-Schmiedeberg s Archives of Pharmacology
Abstract:The study undertakes the development of an atorvastatin-loaded self-nanoemulsifying drug delivery system (SNEDDS) to improve its bioavailability. The SNEDDS were fabricated using oleic acid, Tween 80, and Span 80 by spontaneous emulsification. The SNEDDS were assessed for their particle size distribution, zeta potential, morphology, drug content, surface tension, viscosity, and drug release. The aerodynamic performance of the SNEDDS was evaluated using an Andersen cascade impactor, while the lipid-lowering potential of the SNEDDS was determined in Wistar rats using the analyzer "Microlab 300." The particle size of the SNEDDS ranged from 36 to 311 nm, with a polydispersity index (PDI) of 0.25–0.40. The zeta potential of the SNEDDS fluctuated from − 29.22 to − 38.26 mV, which declined to − 4.55 mV in the case of F5. The chitosan-coated formulation (F5) exhibited a higher viscosity (22.12 mPa s) and lower surface tension (0.056 dyne/cm) than other formulations (F1–F4). The non-coated formulation exhibited a significantly higher burst drug release, followed by a sustained drug release pattern ( p ≤ 0.05) as compared to the coated formulation (F5). The nebulized SNEDDS achieved a dispersed fraction of 87 to 97%, where notably higher aerosol dispersion from F4 was attributed to its smaller particle size and circularity. The inhaled fraction of nebulized SNEDDS was 74–87%. The size of the SNEDDS droplets was the primary determinant affecting the aerodynamic performance of the SNEDDS during nebulization. The chitosan-coated SNEDDS achieved a higher antihyperlipidemic effect than marketed tablets, which shows the suitability of F5 for effective systemic delivery of atorvastatin through the lung.
pharmacology & pharmacy